|
Nov 29
|
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
|
|
Nov 9
|
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
DYAI: Third Quarter Update
|
|
Nov 8
|
Dyadic International Inc (DYAI) Reports Decrease in Q3 Revenue and Net Loss Improvement ...
|
|
Nov 8
|
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
|
|
Sep 19
|
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
|
|
Aug 11
|
DYAI: MoUs Highlight C1 Vaccine Potential
|
|
Aug 9
|
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
|
|
Aug 7
|
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
|
|
Jun 21
|
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
|